Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support
January 18 2022 - 3:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF)
(“
Sirona”) is pleased to announce that it has
renewed an agreement with Luxembourg-based analytics and marketing
specialist CURE Intelligence for marketing intelligence services
and communications support.
The agreement has been signed for an additional
year of services.
“We have been utilizing the powerful tools
provided by CURE Intelligence which keep us informed on relevant
market developments and opportunities that relate to our growing
pipeline of projects. We have benefited greatly from the
intelligence provided to our team members both for scientific and
business development opportunities,” said Dr. Howard Verrico, CEO
of Sirona Biochem. “We look forward to continuing our relationship
with the team at CURE. They have proven their ability to add
significant value and improve our communications and market
intelligence. We continue to fine-tune these services as we utilize
their full potential well beyond communication support.”
"In 2021, Sirona Biochem achieved a very
significant milestone with the launch of a commercial product
containing a Sirona compound. A great deal of progress was made in
business development and scientific research which provides an
excellent basis for further positive developments in 2022. We are
very much looking forward to continuing to provide Sirona Biochem
with relevant market information and contacts, and to raise
awareness of the company and its products among investors, partners
and the trade press," comments Marco Feiten, Managing Director at
CURE Intelligence.
About CURE Intelligence
Founded in 2009, CURE specializes in the field
of media monitoring and analysis, data intelligence, social media
communications and marketing. CURE helps its clients make better
decisions and improve internal and external communication by
effectively combining analytics and marketing.
CURE is a public limited company with its
headquarters in Grevenmacher, Luxembourg and a subsidiary in
Cologne, Germany. CURE works with internationally renowned clients
from Germany, Luxembourg, Brazil, Canada and the U.S. For more
information, please visit www.cure-intelligence.com.
About Sirona Biochem
Corp.Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
located in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:Jonathan WilliamsManaging
DirectorMomentum PRCanadaPhone: 1.450.332.6939Email:
jwilliams@momentumpr.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise. Actual
results, performance or achievement could differ materially from
those expressed in, or implied by, Sirona Biochem’s forward-looking
statements due to the risks and uncertainties inherent in Sirona
Biochem’s business including, without limitation, statements about:
the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval,
producing and marketing its products; unexpected adverse side
effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization;
the scope and validity of patent protection for its products;
competition from other pharmaceutical or biotechnology companies;
and its ability to obtain additional financing to support its
operations. Sirona Biochem does not assume any obligation to update
any forward-looking statements except as required by law.
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sirona Biochem (TSXV:SBM)
Historical Stock Chart
From Aug 2023 to Aug 2024